The CEO's intent to sell a very large block of shares (over 7% of market cap) is a strong negative signal. Monitor for actual execution on Form 4 and any subsequent insider selling patterns.
RDY drugs
RDY drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $14.13entry
- T+1 · 14d ago +1.20%α +0.90% · $14.30
- T+5 · 8d ago +6.51%α +6.43% · $15.05
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Erez Israeli filed a Form 144 notice of intent to sell 460,726 ADRs of Dr. Reddy's Laboratories, valued at approximately $834.6 million based on the filing's reference price. This represents a substantial portion of the CEO's holdings and is a significant insider sale signal.
Key Facts
- CEO Erez Israeli filed Form 144 to sell 460,726 ADRs
- Approximate market value of proposed sale: $834.6 million
- Shares acquired via stock options exercised on 10/28/2026
- Filing date: 2026-11-02; proposed sale date: 10/29/2026 (already past at filing)
- Broker: Merrill Lynch, 75 Rockefeller Plaza, New York
Financial Impact
CEO proposes to sell 460,726 ADRs worth ~$834.6 million, a very large insider sale relative to market cap of $11.8B (approx. 7.1% of market cap)
Risk Factors
- Form 144 is only an intent to sell; the sale may not be completed
- The proposed sale date (10/29/2026) precedes the filing date (11/02/2026), suggesting the sale may have already occurred or is imminent
- Large insider sale by CEO could indicate lack of confidence or personal liquidity needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-068742 |
| Document: 0001628280-26-068742-index.html | 0001628280-26-068742 |
| Document: 0001628280-26-068742.txt | 0001628280-26-068742 |
Track record
73 reports on RDY
7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Viewing Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers